Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026, when a federal advisory panel unanimously backed Moderna’s mRNA-based seasonal influenza shot for adults aged 50 and older. The Vaccines and Related Biological Products Advisory Committee voted on the benefit-risk profile of the candidate, known by its proposed trade name mFlusiva, across two age groups: 50 to 64 and 65 and older. A final FDA decision is expected by early August, and the regulatory path the agency has chosen for each age group will shape how quickly mRNA technology can compete with established flu vaccines.
Why the unanimous VRBPAC vote changes the flu vaccine market
The panel’s decision carries weight because it signals that FDA reviewers and outside experts agree the clinical evidence is strong enough to move toward approval, even though the two age brackets will follow different regulatory tracks. According to the FDA review materials, adults aged 50 to 64 are on track for traditional approval based on efficacy data from the pivotal Study P304. Adults 65 and older, by contrast, would receive accelerated approval, which requires Moderna to complete a Phase 4 confirmatory study demonstrating that mFlusiva performs well against high-dose comparators already on the market.
That split matters for patients and insurers alike. Traditional approval means the FDA considers the existing trial data sufficient to prove clinical benefit in the younger adult group. Accelerated approval for older adults acknowledges that the evidence so far is promising but not yet definitive against the enhanced vaccines, such as high-dose formulations, that are already recommended for people 65 and older. If the confirmatory study shows relative vaccine efficacy above 15 percent versus those high-dose comparators, the mRNA platform would likely earn full traditional approval across all adult age groups, potentially within 18 months of the initial green light.
For the broader flu vaccine market, a successful launch would give payers and health systems a new option in a space long dominated by egg-based and cell-based products. An mRNA-based flu shot could be updated more rapidly to match circulating strains, and the unanimous vote signals that regulators see enough benefit to justify adding another brand to already crowded formularies. How quickly clinicians switch to mFlusiva will depend on real-world performance, pricing, and whether the confirmatory trial confirms an edge over existing high-dose shots.
Phase 3 trial data and the mFlusiva clinical record
The clinical foundation for the panel’s vote rests on two registered Phase 3 trials. The first, a randomized, observer-blind, active-controlled study in adults aged 50 and older, tested a trivalent formulation of mRNA-1010 against a licensed standard-dose influenza vaccine. That trial, described in a New England Journal analysis, used RT-PCR-confirmed, protocol-defined influenza-like illness as its primary endpoint, a rigorous standard that reduces the chance of counting non-flu respiratory infections as vaccine failures.
In that efficacy study, participants were followed through a full Northern Hemisphere flu season, with cases adjudicated by laboratory confirmation and prespecified symptom criteria. Investigators reported that mFlusiva met its primary endpoint, demonstrating noninferiority to the comparator vaccine and evidence of superior protection against at least some A/H3N2 and B lineages. Safety findings were consistent with prior mRNA vaccine experience, with higher rates of short-lived local and systemic reactions such as injection-site pain, fatigue, and headache, but no new serious safety signals identified during the blinded follow-up period.
A second Phase 3 trial enrolled adults aged 18 and older and focused on immunogenicity, reactogenicity, and safety. The FDA briefing document references immunogenicity data from Study P303 Part C, which compared immune responses between mFlusiva and a high-dose comparator in older adults. In that cohort, antibody titers against the vaccine strains were generally higher with the mRNA formulation, supporting the idea that mFlusiva can match or exceed the immune response generated by enhanced-dose products that are already standard for seniors.
Together, these two studies form the evidence package that reviewers presented to the advisory committee at its June 18 session. The distinction between the two trials is not just academic. Study P304 generated the efficacy signal that supports traditional approval for the 50 to 64 age group. Study P303 Part C supplied the immunogenicity bridge to older adults, where the bar is higher because existing high-dose and adjuvanted vaccines already offer better protection than standard-dose shots. The FDA’s decision to require a Phase 4 study for the 65-plus group reflects that gap: strong immune response data alone does not substitute for a head-to-head efficacy trial against the best available alternatives.
Regulators also weighed the overall safety database, which included tens of thousands of participants across age groups. While reactogenicity was higher with the mRNA vaccine, serious adverse events judged related to vaccination were rare. No clear safety imbalances emerged for myocarditis, Guillain–Barré syndrome, or other events that have previously drawn attention in vaccine safety monitoring, though ongoing pharmacovigilance will be required once the product reaches broader use.
A rocky regulatory path before the panel vote
The unanimous recommendation did not come after a smooth journey. Earlier in 2026, Moderna disclosed in an SEC filing that the FDA had issued a refusal-to-file letter for the mRNA-1010 biologics license application. A refusal-to-file letter means the agency determined the initial submission was incomplete or deficient enough that it could not begin a substantive review. Though the agency has not publicly detailed its specific concerns, such letters typically involve missing datasets, formatting problems, or questions about the adequacy of pivotal trials.
Moderna subsequently addressed the agency’s concerns and resubmitted, leading to the advisory committee meeting that took place on June 18. That sequence is significant. A company receiving a refusal-to-file letter and then winning a unanimous panel recommendation within months suggests the resubmission resolved the FDA’s procedural or data concerns. It also means the timeline for a final decision has been compressed. According to the Associated Press, the FDA is expected to act by early August, giving the agency roughly six weeks from the panel vote to issue its ruling.
The episode also underscores how demanding the regulatory bar has become for seasonal flu vaccines, even as public attention has shifted toward other respiratory threats. Unlike during the early COVID-19 vaccine reviews, the agency now has a decade of experience with mRNA platforms and a mature landscape of comparator products. That context likely contributed to the insistence on a robust Phase 3 efficacy trial in middle-aged adults and a postmarketing commitment for seniors rather than a blanket approval based solely on immunogenicity.
Open questions for mFlusiva and the 2026 flu season
Several issues remain unresolved. The full subgroup efficacy numbers from the pivotal Phase 3 trial have not been publicly detailed beyond what appears in the NEJM abstract and the FDA’s meeting slides. Individual voting rationales from VRBPAC members have not been released, so it is unclear whether any panelists expressed reservations despite voting in favor. And no post-meeting statements from HHS or CDC leadership have yet addressed how an mRNA flu shot would be incorporated into existing recommendations that currently prioritize high-dose and adjuvanted products for older adults.
Implementation questions will matter if the FDA grants approval in time for the 2026–2027 flu season. Advisory groups will need to decide whether mFlusiva should be considered interchangeable with current standard-dose vaccines for adults under 65 or positioned as a preferred option. For seniors, its initial status under accelerated approval could lead to more cautious uptake, with some clinicians waiting for confirmatory data before switching patients who are already doing well on high-dose formulations.
Manufacturing and supply will also shape the near-term impact. mRNA platforms can, in theory, be scaled rapidly and updated quickly to match drifted strains, but real-world production capacity and distribution logistics will determine how many doses are available for the upcoming season. If supply is limited, health systems may prioritize younger adults at higher risk of complications, while continuing to rely on existing enhanced vaccines for the oldest patients until more data arrive.
Finally, the confirmatory trial required for older adults will be a critical test of the technology’s competitive edge. A clear efficacy advantage over high-dose comparators could accelerate a broader shift toward mRNA-based flu vaccines and justify premium pricing. A more modest benefit, or a neutral result, would still leave mFlusiva as a viable option but might limit its market share and dampen enthusiasm for further mRNA entrants. For now, the unanimous advisory vote marks a milestone, but the real verdict will come from both the FDA’s final decision and the performance of the vaccine in clinics and communities over the next several flu seasons.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
